0000000000407040
AUTHOR
Ajay J. Kirtane
showing 5 related works from this author
TCT-282 Risk Factors Associated with Adverse Events during Chronic Total Occlusion Percutaneous Coronary Interventions: A sub-Analysis of the OPEN-CT…
2016
Coronary chronic total occlusions (CTOs) are prevalent and the development of the hybrid approach to CTO PCI has been associated with increased technical success rates. However, the incidence and predictors of adverse events (AEs) during CTO PCI remains poorly defined. We analyzed baseline patient
Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials
2021
ABSTRACTEndothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterpri…
TCT-16 Patient and Procedural Characteristics and In-Hospital Outcomes Associated With the Use of Retrograde Recanalization Techniques for Chronic To…
2016
Since the introduction of the Hybrid Algorithm for Chronic Total Occlusion (CTO) PCI, the use of retrograde recanalization techniques has become more common. We sought to identify patient and procedural characteristics necessitating use of retrograde CTO techniques using a multicenter, adjudicated,
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19
2021
Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and ar…
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
2020
AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct…